BioSpace News Archive

Nurix Therapeutics, Inc. (Nurix), a company developing targeted protein modulation drugs, today announced the pricing of its initial public offering of 11,000,000 shares of its common stock at a price to the public of $19.00 per share. All of the shares are being offered by Nurix. The shares are expected to begin trading on The Nasdaq Global Market on July 24, 2020 under the symbol “NRIX.” The gross proceeds from the offering, before deducting u

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic:.

Study suggests GenScript’s cPass™ test is faster, better and safer than traditional tests

iTeos Therapeutics, Inc. announced the pricing of its initial public offering of 10,586,316 shares of common stock at a public offering price of $19.00 per share. All of the shares are being offered by iTeos.